Stock listing
GPW:CTX Captor Therapeutics SA Akcje
Home listing (GPW) of Captor Therapeutics SA
Follow Captor Therapeutics SA into a list and get an email when it puts out news.
Share price · GPW:CTX
52.00 PLN -0.30 (-0.6%)
Close on Nov 20, 2026
- Day range
- 50.50 – 53.10 PLNNov 20, 2026
- Volume
- 6,654 sharesNov 20, 2026
- Market cap
- 329.3M PLNAt the close on Nov 20, 2026 · price × 6.33M shares outstanding
- 52-week range
- 48.10 – 89.20 PLNLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 317,397 PLNMedian day 2,556 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| GPW:CTX · Home | 52.00 PLN | -0.30 (-0.6%) | 6,654 | 53.10 | 53.10 | 50.50 | 52.30 | Close on Nov 20, 2026 |
| Frankfurt:60Q | €11.62 EUR | -0.22 (-1.9%) | — | €11.44 | €11.62 | €11.44 | €11.84 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · GPW:CTX · PLN, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 52.00 | -0.30 | -0.6% | 53.10 | 53.10 | 50.50 | 6,654 | |
| 52.30 | +0.30 | +0.6% | 51.30 | 53.10 | 51.30 | 1,433 | |
| 52.00 | 0.00 | 0.0% | 53.50 | 53.50 | 51.30 | 1,514 | |
| 52.00 | -2.30 | -4.2% | 52.50 | 53.80 | 52.00 | 2,747 | |
| 54.30 | -0.70 | -1.3% | 54.90 | 54.90 | 52.30 | 9,000 | |
| 55.00 | +2.60 | +5.0% | 52.40 | 55.00 | 51.50 | 4,032 | |
| 52.40 | -1.20 | -2.2% | 53.00 | 54.90 | 51.40 | 2,824 | |
| 53.60 | -0.40 | -0.7% | 55.90 | 55.90 | 52.70 | 715 | |
| 54.00 | -1.00 | -1.8% | 52.60 | 55.00 | 52.10 | 2,599 | |
| 55.00 | +4.20 | +8.3% | 51.00 | 56.00 | 51.00 | 11,835 | |
| 50.80 | +0.70 | +1.4% | 50.00 | 51.00 | 50.00 | 4,479 | |
| 50.10 | -0.90 | -1.8% | 51.50 | 51.50 | 49.00 | 5,547 | |
| 51.00 | -2.00 | -3.8% | 53.00 | 53.00 | 50.20 | 5,354 | |
| 53.00 | -0.70 | -1.3% | 53.70 | 54.30 | 52.20 | 2,145 | |
| 53.70 | -1.20 | -2.2% | 54.40 | 55.00 | 53.70 | 8,196 | |
| 54.90 | -1.10 | -2.0% | 55.90 | 55.90 | 54.30 | 2,311 | |
| 56.00 | -0.20 | -0.4% | 56.00 | 57.00 | 55.70 | 9,632 | |
| 56.20 | -0.80 | -1.4% | 55.50 | 57.50 | 55.50 | 2,556 | |
| 57.00 | -0.90 | -1.6% | 57.10 | 57.10 | 56.10 | 1,701 | |
| 57.90 | -0.70 | -1.2% | 58.70 | 58.90 | 56.70 | 2,142 | |
| 58.60 | 0.00 | 0.0% | 58.90 | 58.90 | 56.80 | 998 | |
| 58.60 | +2.20 | +3.9% | 55.80 | 59.60 | 55.20 | 3,792 | |
| 56.40 | -0.60 | -1.1% | 56.60 | 59.50 | 53.30 | 8,567 | |
| 57.00 | -1.40 | -2.4% | 58.40 | 58.90 | 57.00 | 20,526 | |
| 58.40 | -1.20 | -2.0% | 59.60 | 59.80 | 56.60 | 26,322 | |
| 59.60 | -0.40 | -0.7% | 59.60 | 60.90 | 59.60 | 9,991 | |
| 60.00 | -1.30 | -2.1% | 60.00 | 62.00 | 59.60 | 30,504 | |
| 61.30 | -2.70 | -4.2% | 64.10 | 64.40 | 59.20 | 21,957 | |
| 64.00 | -1.50 | -2.3% | 65.40 | 66.70 | 62.50 | 10,032 | |
| 65.50 | -1.50 | -2.2% | 66.40 | 67.00 | 65.50 | 7,277 | |
| 67.00 | +0.80 | +1.2% | 66.90 | 67.30 | 66.30 | 456 | |
| 66.20 | -0.80 | -1.2% | 67.00 | 67.90 | 66.10 | 14,676 | |
| 67.00 | 0.00 | 0.0% | 67.10 | 68.80 | 65.60 | 6,499 | |
| 67.00 | -1.00 | -1.5% | 67.00 | 68.00 | 63.20 | 1,547 | |
| 68.00 | -1.60 | -2.3% | 69.40 | 69.40 | 65.50 | 6,436 | |
| 69.60 | -0.40 | -0.6% | 70.80 | 71.00 | 69.40 | 4,875 | |
| 70.00 | -0.80 | -1.1% | 70.70 | 70.70 | 70.00 | 101 | |
| 70.80 | +0.70 | +1.0% | 70.50 | 70.80 | 70.00 | 626 | |
| 70.10 | +0.30 | +0.4% | 69.80 | 70.90 | 69.80 | 2,252 | |
| 69.80 | -0.50 | -0.7% | 70.30 | 70.30 | 69.20 | 1,127 | |
| 70.30 | -0.80 | -1.1% | 71.00 | 71.00 | 69.00 | 3,148 | |
| 71.10 | -0.40 | -0.6% | 70.20 | 72.40 | 70.20 | 996 | |
| 71.50 | +2.20 | +3.2% | 69.30 | 71.50 | 69.30 | 3,874 | |
| 69.30 | -2.00 | -2.8% | 70.10 | 71.30 | 69.30 | 6,239 | |
| 71.30 | -1.10 | -1.5% | 70.00 | 71.50 | 70.00 | 2,236 | |
| 72.40 | -0.10 | -0.1% | 72.50 | 72.50 | 70.60 | 1,246 | |
| 72.50 | +0.20 | +0.3% | 72.50 | 73.90 | 71.30 | 1,471 | |
| 72.30 | -2.20 | -3.0% | 74.10 | 74.10 | 72.30 | 912 | |
| 74.50 | 0.00 | 0.0% | 73.30 | 74.60 | 72.90 | 5,073 | |
| 74.50 | +2.90 | +4.1% | 71.30 | 74.80 | 71.30 | 2,146 | |
| 71.60 | -1.10 | -1.5% | 72.70 | 72.70 | 71.00 | 2,182 | |
| 72.70 | +2.20 | +3.1% | 70.30 | 72.80 | 69.60 | 11,472 | |
| 70.50 | -0.80 | -1.1% | 71.00 | 71.20 | 70.50 | 413 | |
| 71.30 | -0.20 | -0.3% | 71.10 | 71.90 | 70.60 | 1,337 | |
| 71.50 | +0.50 | +0.7% | 69.50 | 71.50 | 69.50 | 1,176 | |
| 71.00 | 0.00 | 0.0% | 69.60 | 71.00 | 69.00 | 2,450 | |
| 71.00 | -0.90 | -1.3% | 69.70 | 71.90 | 69.40 | 1,910 | |
| 71.90 | +0.90 | +1.3% | 70.00 | 71.90 | 68.30 | 2,014 | |
| 71.00 | -0.10 | -0.1% | 71.00 | 71.60 | 70.00 | 1,890 | |
| 71.10 | -1.90 | -2.6% | 71.30 | 72.00 | 71.10 | 858 | |
| 73.00 | -1.00 | -1.4% | 72.00 | 73.90 | 70.10 | 8,931 | |
| 74.00 | +1.60 | +2.2% | 72.00 | 74.00 | 69.70 | 1,942 | |
| 72.40 | -0.60 | -0.8% | 72.00 | 72.40 | 72.00 | 488 | |
| 73.00 | -0.20 | -0.3% | 73.70 | 73.70 | 71.20 | 792 | |
| 73.20 | +0.40 | +0.5% | 72.90 | 73.80 | 69.20 | 3,701 |
- Ticker
- GPW:CTX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- GPW
- Currency
- PLN
What changed lately
Latest deck · Jun 2, 2026
Q1 2026 Earnings Presentation
Earnings · 11 slides
Latest news
Captor Therapeutics SA on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 6 in all · newest May 30, 2023 · oldest 2022
- Decks
- 23 decks · latest Jun 2, 2026
Where Captor Therapeutics SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| GPW:CTX · Home listing · This page | GPW | Poland | PLN |
| gettex:60Q | gettex | Germany | EUR |
| LS Exchange:A3CNAX | LS Exchange | Germany | EUR |
| Munich:60Q | Munich | Germany | EUR |
| Frankfurt:60Q | Frankfurt | Germany | EUR |
| Stuttgart:60Q | Stuttgart | Germany | EUR |
| Dusseldorf:60Q | Dusseldorf | Germany | EUR |
| Lang & Schwarz:A3CNAX | Lang & Schwarz | Germany | EUR |
Cash and shares
Oct 2, 2025 · Captor Therapeutics — Investor Presentation (October 2025)
- Shares outstanding
- 5,528,709
Valuation
EV/sales 130× against a median of 0.9×: the highest of 6 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 260.5M PLN
- P/E
- Loss
- EV/sales
- 130×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 5.1×
- Gross margin
- 106.8%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Captor Therapeutics SA · GPW:CTX | US$81.11M | US$64.15M | n/a | 130× | n/a | 5.1× | n/a | 0.0× | n/a |
| Rallybio Corporation · NASDAQ:RLYB | US$83.29M | −US$7.40M | 3.1× | −17.1× | n/a | 0.9× | n/a | 0.0× | 0.58 |
| TuHURA Biosciences, Inc. · NASDAQ:HURA | US$82.20M | US$89.50M | n/a | n/a | n/a | 4.3× | n/a | 0.5× | 2.81 |
| 3D Medicines, Inc. · HKEX:1244 | US$81.88M | US$48.45M | n/a | 0.9× | n/a | 1.0× | −49.9% | 0.3× | n/a |
| Kintor Pharmaceutical Ltd · HKEX:9939 | US$81.70M | US$96.94M | n/a | 19.8× | n/a | 5.0× | −612.3% | 1.2× | n/a |
| Nkarta, Inc. · NASDAQ:NKTX | US$81.38M | −US$75.22M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 1.67 |
| Vaxart, Inc. · OTC:VXRT | US$79.89M | US$14.34M | 2.8× | 0.1× | 0.4× | 1.2× | 16.0% | 0.0× | 1.21 |
| Sensorion SAS · EURONEXT:ALSEN | US$79.63M | −US$13.98M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | n/a |
| Adocia SA · EURONEXT:ADOC | US$79.30M | US$77.84M | n/a | 48.1× | n/a | n/a | n/a | n/a | n/a |
| Tiziana Life Sciences Ltd · NASDAQ:TLSA | US$78.98M | US$76.73M | n/a | n/a | n/a | n/a | n/a | n/a | 1.23 |
| Nyrada, Inc. · ASX:NYR | US$78.76M | US$73.21M | n/a | n/a | n/a | 12.5× | n/a | 0.0× | n/a |
| Median of the others | US$80.64M | US$60.83M | 2.9× | 0.9× | 0.4× | 1.1× | −49.9% | 0.0× | 1.23 |
Forecasts
Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.
- Price target
- 91.90 PLN · Analysts' mean
- EPS, year to Dec 2026
- -5.20 · 1 analyst
- Revenue, year to Dec 2026
- 44.6M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Michał Walczak | Chief Executive Officer, Chief Scientific Officer |
| Adam Łukojć | Chief Financial Officer |
| Anna Pawluk | Chief Operating Officer |
Board
| Director | Role |
|---|---|
| Adam Łukojć | Chief Financial Officer |
| Anna Pawluk | Chief Operating Officer |
| Michał Walczak | Chief Executive Officer, Chief Scientific Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Sep 3, 2026 | +0.4% |
| Q1 2026 | Jun 2, 2026 | +0.7% |
| Q3 2025 | Nov 21, 2025 | +0.4% |
| Q2 2025 | Sep 11, 2025 | +2.2% |
| Q1 2025 | Apr 15, 2025 · After close | +0.6% |
| Q3 2024 | Nov 8, 2024 · After close | −4.8% |
| Q2 2024 | Sep 5, 2024 | +10.5% |
| Q1 2024 | May 29, 2024 · After close | −3.7% |
| Q3 2023 | Nov 28, 2023 · After close | +0.7% |
| Q2 2023 | Sep 7, 2023 · After close | −0.8% |
All 17 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2023 | May 30, 2023 · Before open | 0.0% |
| Q4 2022 | Mar 1, 2023 | 0.0% |
| Q3 2022 | Nov 24, 2022 · After close | +1.9% |
| Q2 2022 | Sep 2, 2022 · After close | 0.0% |
| Q1 2022 | May 30, 2022 · After close | +1.1% |
| Q3 2021 | Nov 29, 2021 · After close | −0.4% |
| Quarter to Jun 30, 2021 | Sep 30, 2021 · After close | −1.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q1 2026 Earnings Presentation | Earnings | 11 slides | Jun 2, 2026 |
| Investor Presentation (May 2026) | Investor deck | 72 slides | May 5, 2026 |
| Investor Presentation (October 2025) | Investor deck | 58 slides | Oct 6, 2025 |
| Investor Presentation (September 2025) | Investor deck | 58 slides | September 2025 |
| Investor Presentation (July 2025) | Investor deck | 69 slides | Jul 30, 2025 |
| Investor Presentation (October 2024) | Investor deck | 58 slides | October 2024 |
| Investor Presentation (October 2024) | Investor deck | 58 slides | October 2024 |
| H1 2024 Earnings Presentation | Earnings | 24 slides | Sep 10, 2024 |
| Investor Presentation (March 2024) | Investor deck | 20 slides | Mar 11, 2024 |
| Q3 2023 Earnings Presentation | Earnings | 27 slides | Dec 12, 2023 |
All 23 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2023 Earnings Presentation | Earnings | 26 slides | December 2023 |
| Investor Day (December 2023) | Investor day | 21 slides | Dec 1, 2023 |
| Investor Presentation (October 2023) | Investor deck | 55 slides | October 2023 |
| H1 2023 Earnings Presentation | Earnings | 26 slides | Sep 7, 2023 |
| Investor Presentation (September 2023) | Investor deck | 56 slides | Sep 1, 2023 |
| Q1 2023 Earnings Presentation | Earnings | 30 slides | May 30, 2023 |
| Investor Presentation (September 2022) | Investor deck | 31 slides | Sep 1, 2022 |
| Investor Day (May 2022) | Investor day | 27 slides | May 18, 2022 |
| Investor Day (May 2022) | Investor day | 28 slides | May 18, 2022 |
| Investor Day (May 2022) | Investor day | 37 slides | May 18, 2022 |
| Q3 2021 Earnings Presentation | Earnings | 24 slides | Nov 29, 2021 |
| H1 2021 Earnings Presentation | Earnings | 22 slides | Oct 6, 2021 |
| H1 2021 Earnings Presentation | Earnings | 23 slides | Oct 6, 2021 |
Financials
Annual, in PLN
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.66M | 15.8M | 13.2M | 9.16M | 3.99M | 1.45M | 0 | 16.0K | 474.0K |
| Cost of revenue | 5.31M | 9.40M | 6.30M | 2.09M | 741.0K | 6.60M | 4.46M | 2.59M | 95.0K |
| Gross profit | -652.0K | 6.42M | 6.90M | 7.07M | 3.25M | -6.60M | -4.46M | -2.57M | 379.0K |
| Research and development | 42.9M | 34.7M | 64.8M | 44.2M | 23.1M | 23.6M | 19.2M | 10.7M | 2.50M |
| Selling, general and administrative | 3.92M | 4.13M | 16.1M | 19.6M | 19.5M | 4.20M | 2.44M | 1.10M | 279.0K |
| Operating income | -43.6M | -39.0M | -73.0M | -38.4M | -31.7M | -12.2M | -7.86M | -4.13M | -133.0K |
| Depreciation and amortization | 4.37M | 5.06M | 5.44M | 7.09M | 7.36M | 6.60M | 4.46M | 2.59M | 600.0K |
| EBITDA | -39.2M | -33.9M | -67.6M | -31.3M | -24.4M | -5.61M | -3.40M | -1.54M | 467.0K |
| Interest expense | 283.0K | 437.0K | 323.0K | 657.0K | 863.0K | 393.0K | 430.0K | 266.0K | 46.0K |
| Income before tax | -42.0M | -38.4M | -70.5M | -35.9M | -32.6M | -12.7M | -8.31M | -4.42M | -180.0K |
| Income tax | 57.0K | -26.0K | -1.00K | ||||||
| Net income | -42.0M | -38.4M | -70.6M | -35.9M | -32.6M | -13.1M | -8.74M | -4.42M | -180.0K |
| Earnings per share, basic | -7.61 | -8.25 | -15.19 | -8,610.00 | -7,890.00 | -4.02 | -2.68 | -1.36 | -0.06 |
| Earnings per share, diluted | -8,240.00 | -7,480.00 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 10.7M | 39.3M | 75.7M | 71.0M | 117.9M | 10.7M | 12.3M | 2.45M | 1.59M |
| Short-term investments | 21.4M | 19.9M | |||||||
| Receivables | 1.22M | 38.3M | 12.6M | 9.68M | 11.7M | 2.59M | 1.88M | 4.02M | 515.0K |
| Inventory | 471.0K | 319.0K | -515.0K | ||||||
| Current assets | 33.8M | 78.1M | 88.6M | 101.3M | 130.6M | 13.2M | 14.7M | 6.79M | 2.11M |
| Property, plant and equipment | 10.7M | 12.6M | 12.2M | ||||||
| Total assets | 40.0M | 87.5M | 97.3M | 113.0M | 143.5M | 25.8M | 25.3M | 18.1M | 5.12M |
| Accounts payable | 2.54M | 2.65M | 6.50M | 7.82M | 4.74M | 2.36M | 1.97M | 1.68M | 363.0K |
| Current liabilities | 14.9M | 20.0M | 26.7M | 13.4M | 16.4M | 20.0M | 15.2M | 7.23M | 3.54M |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 214.0K | 214.0K | 211.0K | |
| Total debt | 3.58M | 5.64M | 3.78M | 6.95M | 8.18M | 12.4M | 10.3M | 10.9M | 2.83M |
| Total liabilities | 16.5M | 23.0M | 28.1M | 16.7M | 19.3M | 26.8M | 21.0M | 14.6M | 4.98M |
| Shareholders' equity | 23.5M | 64.5M | 69.2M | 96.3M | 124.2M | -1.00M | 4.28M | 3.43M | 144.0K |
| Shares outstanding | 5.52M | 4.66M | 4.65M | 4.17M | 4.13M | 3.26M | 3.26M | 3.26M | 3.26M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -36.3M | -31.9M | -52.2M | -22.9M | -28.5M | -595.0K | 4.39M | -2.13M | 2.10M |
| Capital spending | -210.0K | -424.0K | -3.00M | -892.0K | -5.11M | -212.0K | -229.0K | -100.0K | 0 |
| Free cash flow | -36.5M | -32.1M | -55.2M | -23.8M | -33.6M | -807.0K | 4.17M | -2.23M | 2.10M |
| Cash from investing | -21.1M | 273.0K | 19.9M | -17.6M | -5.11M | -212.0K | -229.0K | -100.0K | |
| Cash from financing | 28.9M | -4.84M | 36.9M | -6.33M | 140.9M | -881.0K | 5.73M | 3.09M | -513.0K |
| Change in cash | -28.5M | -36.4M | 4.67M | -46.9M | 107.3M | -1.69M | 9.89M | 861.0K | 1.58M |
Cap table
Built by 6ix from Captor Therapeutics SA’s releases
- Common shares
- 6,333,397
- Fully diluted
- 6,333,397
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 6,333,397 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 6,333,397 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Adam Łukojć | Chief Financial Officer · Since at least Nov 5, 2026 |
| Anna Pawluk | Chief Operating Officer · Since at least Nov 5, 2026 |
| Michał Walczak | Chief Executive Officer, Chief Scientific Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Captor Therapeutics SA.